课题基金 / 基金详情

项目摘要

项目成果

DON KREUTZER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Background: Significant effort has been invested in developing implantable glucose sensors for diabetics, but current sensors last only hrs to days due to loss of function. This loss of sensor function is in part the result of the tissue response triad of inflammation, fibrosis and vessel regression surrounding the glucose sensor. Since mast cells play a key role in all these processes we have developed the following hypothesis Grant Hypothesis: Mast cells, and their activation products, directly and indirectly contribute to the lose of glucose sensor function in vivo, by releasing agents that directly biofoul glucose sensors, as well as by releasing pro-inflammatory agents (e.g. mast cell derived vasoactive and chemotactic factors) that promote inflammation and tissue injury, and thereby are responsible for loss of sensor function both short term and long term in vivo. Study Design: Using our recently developed mouse model of implantable glucose sensors we will determine the impact of deletion and or inhibition of mast cells and the production on sensor function in vivo. Specific Aims: SPECIFIC AIM 1: To Determine the Role of Mast Cells and Mast Cell Activation, in the Loss of Glucose Sensor Function and Lifespan in Vivo SPECIFIC AIM 2: To Determine the Direct Impact of Mast Cells (MCs), and MCs Products, on Glucose Sensor Function in Vitro SPECIFIC AIM 3: To Identify Mast Cell Derived Factors that Contribute to the Loss of Glucose Sensor Function in Vivo and in Vitro.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Importance of interleukin-1 and interleukin-1 receptor antagonist in short-term glucose sensor function in vivo.
IL-1 和 IL-1 受体拮抗剂在体内短期葡萄糖传感器功能中的重要性。
DOI: 10.1177/193229681000400506
发表时间: 2010
期刊: Journal of diabetes science and technology
影响因子: 5
作者: [Klueh,Ulrike, Liu,Zenghe, Feldman,Ben, Kreutzer,Don]
通讯作者: Kreutzer,Don
DOI: 10.1016/j.biomaterials.2010.02.023
发表时间: 2010-06
期刊: BIOMATERIALS
影响因子: 14
作者: [Klueh, Ulrike, Kaur, Manjot, Qiao, Yi, Kreutzer, Donald L.]
通讯作者: Kreutzer, Donald L.
A novel inline platform provides an advanced drug delivery device foroptimized diabetes therapy
  • 批准号:
    10736126
  • 项目类别:
  • 资助金额:
    $68.79万
  • 财政年份:
    2023
  • 负责人:
    DON KREUTZER
  • 依托单位:
Development and Validation of Novel Coatings that Extend Glucose Sensor Accuracy and Lifespan in vivo
Use of Stem Cells to Enhance and Extend Continuous Glucose Monitoring in Vivo
Impact of the Vascular System and CGM
海外基金